|
The Immunohistochemistry Antibody Company
|
- Home
-
Products
- All Antibodies
- IHC-plus Antibodies
-
Services
- Immunohistochemistry Studies
- Tissue Cross-Reactivity Screening
- Distributors
-
Resources
- About our Tissue Bank
- Customer Support
- How to Buy
- IHC-plus Protocol
- LSBio Media
- Publications
- Antibody Reports
-
Company
- About LifeSpan
- Press Releases
- Holiday Schedule
- Contact Us
|
|
Endometrial Cancer Screen 3 Tissue Microarray - LS-SEMCA3
This tissue microarray is available for use in LSBio Immunohistochemistry Studies only.
|
|
| Catalog ID: |
LS-SEMCA3 |
| Product Name: |
Endometrial Cancer Screen 3 |
| Description: |
36 endometrial cancer (predominantly adenocarcinoma) specimens with progressive stage/grade, and 12 normal specimens (duplicate cores) |
| Format: |
FFPE |
| Category: |
Human Tumor Progression |
| QA/QC: |
H&E reviewed; IHC validated with a positive control antibody |
| Storage: |
Short term RT; Long term 4ºC |
| Clinical History: |
No |
| Tissue Marker: |
No |
| Stage/Grade: |
Yes |
| Core Diameter: |
1.5 mm |
| Core Thickness: |
4 µm |
| Cases: |
48 |
| Cores: |
96 |
| Slides Per Set: |
1 |
LS-SEMCA3 Tissue Microarray Map
Slide Number 1
| LABEL | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | | A | End | End | End | End | End | End | End | End | End | End | End | End | | B | End | End | End | End | End | End | End | End | End | End | End | End | | C | End | End | End | End | End | End | End | End | End | End | End | End | | D | End | End | End | End | End | End | End | End | End | End | End | End | | E | End | End | End | End | End | End | End | End | End | End | End | End | | F | End | End | End | End | End | End | End | End | End | End | End | End | | G | End | End | End | End | End | End | End | End | End | End | End | End | | H | End | End | End | End | End | End | End | End | End | End | End | End |
|
Diagnosis Type Legend| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue LegendEndometrium (End);
LS-SEMCA3 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Stage |
|---|
| 1 | A1 | Human | F | 44 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A2 | Human | F | 37 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A3 | Human | F | 45 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A4 | Human | F | 45 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A5 | Human | F | 44 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A6 | Human | F | 72 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A7 | Human | F | 34 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A8 | Human | F | 48 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A9 | Human | F | 47 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A10 | Human | F | 40 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A11 | Human | F | 52 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | A12 | Human | F | 40 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B1 | Human | F | 44 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B2 | Human | F | 37 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B3 | Human | F | 45 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B4 | Human | F | 45 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B5 | Human | F | 44 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B6 | Human | F | 72 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B7 | Human | F | 34 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B8 | Human | F | 48 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B9 | Human | F | 47 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B10 | Human | F | 40 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B11 | Human | F | 52 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | B12 | Human | F | 40 y | Endometrium (End) | Normal | Benign non-neoplastic | | |
| 1 | C1 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | C2 | Human | F | 39 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | I |
| 1 | C3 | Human | F | 42 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | C4 | Human | F | 65 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | C5 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C6 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C7 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C8 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C9 | Human | F | 49 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C10 | Human | F | 33 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | I-II |
| 1 | C11 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | C12 | Human | F | 48 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | D1 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | D2 | Human | F | 39 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | I |
| 1 | D3 | Human | F | 42 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | D4 | Human | F | 65 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I |
| 1 | D5 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D6 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D7 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D8 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D9 | Human | F | 49 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D10 | Human | F | 33 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | I-II |
| 1 | D11 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | I-II |
| 1 | D12 | Human | F | 48 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | E1 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E2 | Human | F | 54 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E3 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E4 | Human | F | 68 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E5 | Human | F | 56 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E6 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | E7 | Human | F | 40 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E8 | Human | F | 58 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E9 | Human | F | 66 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | E10 | Human | F | 57 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | E11 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II-III |
| 1 | E12 | Human | F | 48 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | F1 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F2 | Human | F | 54 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F3 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F4 | Human | F | 68 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F5 | Human | F | 56 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F6 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II |
| 1 | F7 | Human | F | 40 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F8 | Human | F | 58 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F9 | Human | F | 66 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II |
| 1 | F10 | Human | F | 57 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | F11 | Human | F | 43 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II-III |
| 1 | F12 | Human | F | 48 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | II-III |
| 1 | G1 | Human | F | 58 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II-III |
| 1 | G2 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N1M0 | III |
| 1 | G3 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | G4 | Human | F | 51 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | III |
| 1 | G5 | Human | F | 46 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | G6 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N0M0 | III |
| 1 | G7 | Human | F | 67 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | III |
| 1 | G8 | Human | F | 52 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | G9 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N0M0 | III |
| 1 | G10 | Human | F | 36 y | Endometrium (End) | Undifferentiated carcinoma | Malignant | T2N0M0 | |
| 1 | G11 | Human | F | 58 y | Endometrium (End) | Squamous cell carcinoma | Malignant | T1N0M0 | II-III |
| 1 | G12 | Human | F | 44 y | Endometrium (End) | Stromal sarcoma | Malignant | | |
| 1 | H1 | Human | F | 58 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | II-III |
| 1 | H2 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N1M0 | III |
| 1 | H3 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | H4 | Human | F | 51 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | III |
| 1 | H5 | Human | F | 46 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | H6 | Human | F | 53 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N0M0 | III |
| 1 | H7 | Human | F | 67 y | Endometrium (End) | Adenocarcinoma | Malignant | T2N0M0 | III |
| 1 | H8 | Human | F | 52 y | Endometrium (End) | Adenocarcinoma | Malignant | T1N0M0 | III |
| 1 | H9 | Human | F | 60 y | Endometrium (End) | Adenocarcinoma | Malignant | T3N0M0 | III |
| 1 | H10 | Human | F | 36 y | Endometrium (End) | Undifferentiated carcinoma | Malignant | T2N0M0 | |
| 1 | H11 | Human | F | 58 y | Endometrium (End) | Squamous cell carcinoma | Malignant | T1N0M0 | II-III |
| 1 | H12 | Human | F | 44 y | Endometrium (End) | Stromal sarcoma | Malignant | | |
Copyright © 2013 LifeSpan BioSciences, Inc. All Rights Reserved
